Novo Nordisk and Eli Lilly Just Got Some Fantastic News

A NIH-funded mouse study just handed the GLP-1 bulls a fresh talking point: semaglutide extended lifespan and slowed aging in older mice, according to the findings. NVO makes semaglutide, and LLY competes in the same GLP-1 class.

The study found semaglutide improved muscle and cognitive function and reduced inflammation in the aging animals. Those are the mechanisms behind the lifespan benefit, and they point to potential uses well beyond the drugs' current profile.

The demand backdrop is the real driver for equity holders. Forecasts cited in the coverage call for 25 million Americans on GLP-1 treatments by 2030 and a market reaching $190 billion by 2035. Interpretation: if longevity-linked benefits gain credibility, they could widen the addressable patient pool and support those volume projections for both NVO and LLY.

The caveat matters. This is a mouse study, not human trial data, and nothing in it changes current label indications or near-term earnings. The market impact here is narrative and sentiment, not a confirmed revenue catalyst. MRK is tagged in the coverage, but the findings concern semaglutide and the GLP-1 class, so any read-through to MRK is indirect at best.